此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

NX-5948联合其他药物治疗成人B细胞恶性肿瘤的研究

2026年11月13日 更新者:Nurix Therapeutics, Inc.

一项开放标签、多中心1b/2期研究,旨在评估NX-5948联合其他药物治疗成人B细胞恶性肿瘤的安全性和疗效

The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line or higher (2L+) relapsed/refractory (R/R) or first-line (1L) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

研究概览

地位

招聘中

条件

干预/治疗

详细说明

Bexobrutideg is an investigational drug designed to target a protein called Bruton tyrosine kinase (BTK), which helps cancer cells grow in certain blood cancers like CLL and SLL. Bexobrutideg is a protein degrader, which means it finds and destroys the BTK in the cell. Venetoclax, rituximab, and obinutuzumab are approved medications that are used to treat CLL/SLL.

The study will look at:

  • How safe bexobrutideg is for patients with CLL or SLL when taken with these other treatments
  • The effects of bexobrutideg in the body when taken with these other treatments
  • How well bexobrutideg treats CLL or SLL when taken with these other treatments

研究类型

介入性

注册 (估计的)

150

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • California
      • Irvine、California、美国、92618
        • 尚未招聘
        • City of Hope Orange County Lennar Foundation Cancer Center
    • Colorado
      • Aurora、Colorado、美国、80012
        • 招聘中
        • Rocky Mountain Cancer Centers
    • Florida
      • Coral Gables、Florida、美国、33146
        • 尚未招聘
        • University of Miami
    • Kansas
      • Kansas City、Kansas、美国、66160
        • 尚未招聘
        • University of Kansas Cancer Center
    • Nevada
      • Las Vegas、Nevada、美国、89169
        • 尚未招聘
        • Comprehensive Cancer Centers of Nevada
    • New Jersey
      • Belleville、New Jersey、美国、07109
        • 尚未招聘
        • New Jersey Cancer Care
    • Oregon
      • Eugene、Oregon、美国、97401
        • 招聘中
        • Oncology Associates of Oregon
    • Pennsylvania
      • Pittsburgh、Pennsylvania、美国、15232
        • 招聘中
        • UPMC Hillman Cancer Center
    • Tennessee
      • Nashville、Tennessee、美国、37203
        • 招聘中
        • SCRI Oncology Partners
    • Texas
      • Tyler、Texas、美国、75702
        • 招聘中
        • Texas Oncology - Northeast

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Key Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
  • Adequate organ and bone marrow function
  • Measurable disease by computed tomography (CT) per iwCLL
  • For R/R CLL/SLL, prior therapy must include treatment with a Bruton tyrosine kinase inhibitor (BTKi)
  • For 1L CLL/SLL, confirmed previously untreated CLL/SLL with a clinical indication for systemic treatment that meets iwCLL criteria
  • Must sign an informed consent form indicating understanding of the study purpose and procedures and willingness to participate

Key Exclusion Criteria:

  • Known or suspected prolymphocytic leukemia or Richter's transformation at any time preceding enrollment
  • Investigational agent or anticancer therapy within 5 half-lives or 14 days (whichever is shorter) prior to planned start of study treatment
  • Radiotherapy within 2 weeks of the first dose of study drug except for focal palliative radiation
  • Use of systemic corticosteroids (>20 mg/day prednisone or equivalent) within the 7 days prior to initiation of study treatment excepting those used as prophylaxis for radiodiagnostic contrast
  • Previously treated with a BTK degrader
  • Previously treated with a BCL-2 inhibitor (BCL-2i) unless eligible for retreatment
  • Known central nervous system (CNS) lymphoma or leukemia
  • Myocardial infarction, unstable angina, unstable symptomatic ischemic heart disease, placement of a coronary arterial stent, or any other significant cardiac condition within 6 months of planned start of study treatment
  • Thromboembolic events, stroke, or intracranial hemorrhage within 6 months of planned start of study treatment

Note: Other Inclusion/Exclusion criteria may apply as defined in the protocol.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:NX-5948 + 维奈托克

Administered orally once daily as a capsule

其他名称:
  • bexobrutideg

Administered orally once daily as a tablet per prescribing information

实验性的:NX-5948 + venetoclax + rituximab

Administered orally once daily as a capsule

其他名称:
  • bexobrutideg

Administered orally once daily as a tablet per prescribing information

Administered as an intravenous (IV) infusion per prescribing information

实验性的:NX-5948 + 维奈托克 + 奥滨尤妥珠单抗

Administered orally once daily as a capsule

其他名称:
  • bexobrutideg

Administered orally once daily as a tablet per prescribing information

Administered as an IV infusion per prescribing information

研究衡量的是什么?

主要结果指标

结果测量
大体时间
发生治疗相关不良事件的受试者数量
大体时间:最长约7年
最长约7年

次要结果测量

结果测量
措施说明
大体时间
Objective response rate as determined by investigator
大体时间:Up to approximately 7 years

The percentage of participants with response as determined according to 2018 iwCLL guidelines; response includes complete response (CR)/CR with incomplete marrow recovery (CRi), partial response (PR), PR with lymphocytosis (PR-L), and nodular PR

Up to approximately 7 years
Duration of response as determined by investigator
大体时间:Up to approximately 7 years

Time from the date of the first response to the date of documented progressive disease or death due to any cause, whichever is earlier

Up to approximately 7 years
Progression-free survival as determined by investigator
大体时间:Up to approximately 7 years

Time from the date of the first dose of study drug to the date of documented progressive disease or death due to any cause, whichever is earlier

Up to approximately 7 years
Complete response rate as determined by investigator
大体时间:Up to approximately 7 years

The percentage of participants with CR or CRi as determined according to 2018 iwCLL guidelines; includes CR + CRi for participants with CLL.

Up to approximately 7 years
Time to response as determined by investigator
大体时间:Up to approximately 7 years

Time from the start date of study treatment to the date of the first assessment of a response

Up to approximately 7 years
Overall survival
大体时间:Up to approximately 7 years

Time from the start date of study treatment to the date of death from any cause

Up to approximately 7 years
Pharmacokinetic profile of NX-5948
大体时间:Up to approximately 1 year

NX-5948 concentrations in blood samples

Up to approximately 1 year
Pharmacokinetic profile of venetoclax
大体时间:Up to approximately 1 year

Venetoclax concentrations in blood samples

Up to approximately 1 year
Change from baseline in Global Health Status/Quality of Life on the European Organization for Research and Treatment of Cancer QoL Questionnaire-Core 30 (EORTC QLQ-C30)
大体时间:Baseline and up to approximately 27 months

Percentage of participants with a clinically meaningful change from baseline using the EORTC QLQ-C30 questionnaire to assess the overall quality of life

Baseline and up to approximately 27 months
Change from baseline in European Quality of Life 5-Dimensions, 5-Level Questionnaire (EQ-5D-5L)
大体时间:Baseline and up to approximately 27 months

Percentage of participants with a clinically meaningful change from baseline using the EQ-5D-5L questionnaire to assess health outcomes

Baseline and up to approximately 27 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 研究主任:Study Director、Nurix Therapeutics, Inc.

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年9月30日

初级完成 (估计的)

2033年5月1日

研究完成 (估计的)

2033年5月1日

研究注册日期

首次提交

2026年4月2日

首先提交符合 QC 标准的

2026年4月2日

首次发布 (实际的)

2026年4月9日

研究记录更新

最后更新发布 (实际的)

2026年11月16日

上次提交的符合 QC 标准的更新

2026年11月13日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.